HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 8, August 2016 – Novel Technologies for Antibody Drug Discovery in Japan       » Global Experts Convene to Discuss China's Plan for Diabetes Prevention and Rehabilitation in 2016       » Butterflies Offer Climate Scientists Ecological Insights       » Thermal Stability of Camelid Single Domain VHH Antibody       » That Gut Feeling: How A Healthy Digestive System Has Everything To Do With It       » World Heart Day - At the Heart of Health      
BIOBOARD - SINGAPORE
Singapore Scientists Lead in the Discovery of Gene Responsible for Fatal Drug Allergy

A team of researchers led by Prof Liu Jianjun from A*STAR鈥檚 Genome Institute of Singapore (GIS) has discovered that the presence of a gene allele known as HLA-B*13:01 could cause a severe adverse drug reaction (ADR) to dapsone, which could be fatal. The important discovery will lead to the development of HLA-B*13:01-based diagnostic tests, which will identify high-risk individuals of this potentially life-threatening condition, and help improve the safety of dapsone therapy.

Dapsone (diamino-diphenyl sulfone) is a drug used in the treatment of various forms of infectious and inflammatory diseases and is commonly prescribed for the treatment of leprosy. Up to 3.6% of individuals treated with dapsone develop a severe adverse drug reaction known as dapsone hypersensitivity syndrome (DHS) and between 11% and 13% die as a result. This is alarming as no test is currently available to predict the risk of DHS in patients.

Prof Liu, Senior Group Leader of Human Genetics and Deputy Director of Research Programmes at the GIS, and his colleagues performed a genome-wide association study on 76 DHS patients and 1,304 controls, and discovered that the presence of a particular HLA-B molecule (called HLA-B*13:01) increased the risk of DHS. Individuals carrying a single copy of HLA-B*13:01 run 34 times the risk of being hit by DHS as compared to those who do not carry this allele. The scientists further found that the risk is magnified 100 times for those who carry two copies of HLA-B*13:01.

This study also showed that the allele HLA-B*13:01 has a sensitivity and specificity of above 85% in predicting the risk of DHS. Additionally, the implementation of HLA-B*13:01-based diagnostic testing reduces the risk of DHS by an impressive seven-fold.

Click here for the complete issue.

NEWS CRUNCH  
news CPhI's Pre-Connect Congress outlines current trends in pharma
news World Population Day 2016
news NUS Student Clinches Top Prize at National Smart Mapping Competition with Cutting-Edge Food Security Solution
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices & Healthcare Technology
July:
Water Technology and Management
August:
Novel Technologies for Antibody Drug Discovery in Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Big Data in Healthcare
December:
Evidence-based TCM
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com or Mr Edward
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy